Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Marker Therapeutics

10/08/2026 21:58

Marker Therapeutics Inc MRKR.OQ MRKR.O is expected to  show a fall in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2026
The Houston Texas-based  company is expected to report a 20.8% decrease in revenue to $682 thousand from $861 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Marker Therapeutics Inc is for a loss of 22 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Marker Therapeutics Inc is $8.00, about 614.3% above its last closing price of $1.12
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.18
-0.18
-0.16
Beat
12.7
Dec. 31 2026
-0.20
-0.20
-0.09
Beat
54.2
Sep. 30 2025
-0.43
-0.45
-0.12
Beat
73.3​
Jun. 30 2025
-0.40
-0.41
-0.29
Beat
29.3
​​Mar. 31 2025
-0.66
-0.49
-0.36
Beat
26.6
Dec. 31 2024
-0.16
-0.22
-0.42
Missed
-91.3​
Sep. 30 2024
-0.39
-0.39
-0.26
Beat
33.3
Jun. 30 2024
-0.43
-0.43
-0.25
Beat
41.9
This summary was machine generated August 10 at 20:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)